Local News: Seoul, South Korea 

 | 

Sign Up

 | 

Sign In

Amgen News Editors

News Widget

Display the Amgen news headlines on your website.

Get the Topix Headlines Widget

Share & bookmark

RSS icon mobile icon

Amgen News

News on Amgen (Ticker: AMGN) continually updated from thousands of sources around the net.

4 hrs ago | Sys-Con Media

Amgen to Present at the Leerink Swann Global Healthcare Conference

Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com , under Investors.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry

16 hrs ago | Seeking Alpha

5 Biotech Stocks Undervalued By EPS Trends

Interested in finding undervalued stocks? For ideas on where to look, we ran a screen you might be interested in.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Healthcare Industry, Biology, Science, Albany Molecular Research

Sat Feb 11, 2012

Wall St. Cheat Sheet

Healthcare Sector Review: Watson Files for FDA Approval, Biosimilar Drug Guidelines

Johnson & Johnson , Pfizer Inc. A ,A Amgen, Inc. A : The FDA released guidelines for the first shortcut to the U.S. market for "biosimilar" drugs, less expensive versions of expensive and complex medicines made from biological matter.

Comment?

Related Topix: Biotech, Johnson and Johnson, Medicine, Healthcare Industry, Pfizer, Merck , Watson Pharmaceuticals, Pharmaceuticals

Fri Feb 10, 2012

Penny PayDay

ImmunoCellular (OTCBB: IMUC) Shareholder Update Validates Strong Potential for Growth

Tallahassee, FL 2/10/12 - Biotechnology topics are hot in the investment community.

Comment?

Related Topix: Biotech, Science / Technology, Immunology, Biology, Science, Medicine, Healthcare Industry, Biogen Idec, Health, Brain Cancer

ASHP

Industry Panel Discusses Status of Personalized Medicine

Koch said personalized medicine involves knowing the molecular pathophysiology of the patient's disease and differentially diagnosing the disease on the basis of those underlying molecular defects.

Comment?

Related Topix: Health, Lung Cancer, Mountain View, CA, Biotech, Medicine, Healthcare Industry, Oncology, Nodality

Minyanville

Buzz on the Street: Hurtling Through Chaos

All day and every day, some of the stock market's best and brightest traders and money managers share their ideas, insights and analysis in real-time on Minyanville's Buzz & Banter .

Comment?

Related Topix: Healthcare Law, Law, Dendreon, Biotech, Healthcare Industry

Thu Feb 09, 2012

AmericanBankingNews.com

Oppenheimer Analysts Downgrade Amgen Shares to "Perform"

Amgen was downgraded by research analysts at Oppenheimer from an "outperform" rating to a "perform" rating in a report issued on Thursday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen, Oppenheimer Holdings, Financial Services, Investment Services, Biology, Science, Epogen, Procrit, Epoetin Alfa (generic), Medication, Neupogen, Filgrastim (generic)

Wall Street Journal

FDA Sets Shortcut Path for Biosimilar Drugs

The Food and Drug Administration on Thursday created the first shortcut to the U.S. market for "biosimilar" drugs - cheaper versions of expensive and complex medicines made from biological matter.

Comment?

Related Topix: Rheumatoid Arthritis, Medicine, Health, Biotech, Healthcare Industry, Johnson & Johnson, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals, Food, J and J Snack Foods

Stock Market Review

Forget Big Pharma, It's Time For A Biotech ETF - ETF News And Commentary

Recent earnings reports from a few bellwethers in the pharmaceutical space suggest that more pain is likely ahead for the beleaguered industry.

Comment?

Related Topix: Biotech, Science / Technology, Pfizer, Medicine, Healthcare Industry, Eli Lilly, Amgen

Wall St. Cheat Sheet

Healthcare Sector Review: Nestle Leads Round 2 in Pfizer Buy, Sangamo Q4 Report

Amgen, Inc. is discussing data from its supplemental Biologics License Application for Xgeva to treat men with castration-resistant prostate cancer at high risk of developing bone metastases at today's FDA's Oncologic Drugs Advisory Committee meeting.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Sangamo Biosciences, Startups, Banking, Deutsche Bank AG, Financial Services, Mead Johnson

Wed Feb 08, 2012

Erie Times News

Business briefs from across the nation and around the world

An initial public offering of a tiny slice of Caesars Entertainment Corp. is allowing dozens of investors who bought into what once was the world's largest gambling company to get out -- perhaps with smaller losses than they might have seen.

Comment?

Related Topix: Cell Phones, Cellphones, Electronics, Biotech, Medicine, Healthcare Industry

Wall St. Cheat Sheet

Healthcare Business Recap: Amgen's Limitation, Sanofi's Earnings

Sanofi's fourth quarter income of Genzyme and emerging markets offsets the death of patents and the effect of European Union rigor.

Comment?

Related Topix: Biotech, SanofiSynthlabo, Medicine, Amgen, Healthcare Industry, Genzyme General, GlaxoSmithKline

NewsOK.com

FDA panel votes against Xgeva for prostate cancer

A panel of cancer experts voted against a new use for Amgen 's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients The Food and Drug Administration 's cancer drug panel voted 12-1 that the benefits of the drug did not outweigh its risks, which ... (more)

Comment?

Related Topix: Prostate Cancer, Health, Biotech, Healthcare Industry

Seeking Alpha

Medgenics' Disruptive Biotechnology Is One To Watch

Medgenics has, what I believe to be, the most disruptive biotechnologies of the last 20 years.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Healthcare Industry

Freshnews

Amgen to Discuss Application for New Use of XGEVAA (denosumab) at...

Amgen will discuss the data from the supplemental Biologics License Application for XGEVA to treat men with castration-resistant prostate cancer at high risk of developing bone metastases at today's meeting of the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee .

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Prostate Cancer, Health, Healthcare Law, Law, Food and Drug Administration

Tue Feb 07, 2012

AmericanBankingNews.com

Amgen (AMGN) Shares Upgraded to "Outperform" by Zacks Investment Research Analysts.

Amgen was upgraded by Zacks Investment Research from a "neutral" rating to an "outperform" rating in a research note issued to investors on Tuesday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen

Sys-Con Media

Binswanger and Kidder Mathews Named Exclusive Agent for Sublease of...

Binswanger and Kidder Mathews Named Exclusive Agent for Sublease of Class A Lab and Office Space in South San Francisco, California PHILADELPHIA, PA -- -- 02/07/12 -- Binswanger and Kidder Mathews have been named exclusive agents by Amgen, Inc.

Comment?

Related Topix: Marketwire, Biotech, Medicine, Healthcare Industry, South San Francisco, CA

Wall St. Cheat Sheet

Stock Analysts Reveal News on Sprint, Dendreon, Yum! Brands, Teva

Sprint Nextel Corp. : FBR's channel checks indicate Sprint's solid execution continues and the firm reiterates an Outperform rating on the stock ahead of the company's Q4 results on February 8. FBR believes Sprint is on track to exceed consensus expectations in FY12.

Comment?

Related Topix: Biotech, Teva Pharmaceutical Industries, Yum Brands, Sprint Nextel, Telecom, Restaurant Management, IT Services, Dendreon, Medicine, Amgen, Healthcare Industry

Mon Feb 06, 2012

Wall St. Cheat Sheet

Healthcare Sector Review: Orexigen Reaches Agreement with FDA, Amgen's Xgeva

Orexigen Therapeutics announced that it has reached agreement with the U.S. FDA on a Special Protocol Assessment, or SPA, for the Contrave outcomes trial.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Medicine, Healthcare Industry, Amgen, Orexigen Therapeutics, Food and Drug Administration

AmericanBankingNews.com

Amgen (AMGN) Shares Downgraded to "Sell" by Lazard Capital Analysts

Amgen was downgraded by investment analysts at Lazard Capital from a "neutral" rating to a "sell" rating in a note issued to investors on Monday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Amgen, Biology, Science, Medication, Neupogen, Filgrastim (generic)

Also on Topix